Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria
| Filename | 183. Metz et al.,Retreatm. Omalizumab in CSU.JAMA Derm 2014.pdf |
| Filesize | 174.57 KB |
| Version | o.183 |
| Date added | June 6, 2020 |
| Downloaded | 0 times |
| Category | Original Work |
| Authors | Metz, M., Ohanyan, T., Church, M. K., and Maurer, M. |
| Citation | Metz, M., Ohanyan, T., Church, M. K., and Maurer, M.: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Derm. 2014: 150; 288-290. |
| Corresponding authors | Maurer, M. |
| DocNum | O.183 |
| DocType | |
| Edition; Page | 150; 288-290 |
| IF | 4.43 |
| Publisher | JAMA Derm. |
| ReleaseDate | 2014 |
IMPORTANCE: Omalizumab has emerged as a novel and effective treatment option for patients with antihistamine-resistant chronic urticaria. It is unclear whether patients with recurrent urticaria symptoms after discontinuation of omalizumab treatment can benefit from retreatment.
OBJECTIVE: To assess the response of patients with chronic urticaria who receive omalizumab retreatment.
DESIGN,SETTING,ANDPARTICIPANTS: Retrospective analyses were conducted of outpatients treated at an urticaria specialist center of a university hospital. Participants included 25 consecutive patients (aged 18-74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omalizumab treatment, experienced relapse after discontinuation of treatment, and received retreatment with omalizumab.
INTERVENTIONS Subcutaneous treatment with omalizumab (150-600mg/mo).
MAINOUTCOMESANDMEASURES: Response after retreatment was assessed by the urticaria activity score in patients with chronic spontaneous urticaria and by trigger threshold testing (in patients with cold urticaria or symptomatic dermographism) and/or a carefully determined history (in patients with cholinergic urticaria, solar urticaria, or pressure urticaria). Adverse events were documented.
RESULTS: All patients experienced complete response after retreatment. None of the patients reported relevant adverse events during omalizumab treatment and retreatment.
CONCLUSIONSANDRELEVANCE: Omalizumab retreatment is effective and safe in patients with chronic urticaria who have benefited from initial omalizumab treatment.
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.